Prevalence of appropriate cardioverter-defibrillator shocks in 1038 consecutive patients with implantable cardioverter-defibrillators

Am J Ther. 2009 Jul-Aug;16(4):323-5. doi: 10.1097/MJT.0b013e3181727a59.

Abstract

During a 33-month follow-up of 1038 consecutive patients who had implantable cardioverter-defibrillators, appropriate shocks occurred in 329 of 1038 patients (32%). Appropriate shocks occurred in 101 of 380 patients (27%) treated with beta-adrenergic blockers alone; in 31 of 95 patients (33%) treated with amiodarone alone; in 39 of 149 patients (26%) treated with beta-blockers plus amiodarone; in 11 of 28 patients (39%) treated with sotalol alone; and in 147 of 386 patients (38%) treated with no beta-blockers, amiodarone, or sotalol (P < 0.001 comparing patients treated with beta-adrenergic blockers alone with patients treated with no beta-blockers, amiodarone, or sotalol; and P < 0.01 comparing patients treated with beta-blockers plus amiodarone with patients treated with no beta-blockers, amiodarone, or sotalol). In conclusion, patients having implantable cardioverter-defibrillators should also be treated with beta-adrenergic blockers to reduce the frequency of appropriate shocks.

Publication types

  • Comparative Study

MeSH terms

  • Adrenergic beta-Antagonists / administration & dosage
  • Adrenergic beta-Antagonists / therapeutic use
  • Age Factors
  • Aged
  • Amiodarone / administration & dosage
  • Amiodarone / therapeutic use
  • Anti-Arrhythmia Agents / administration & dosage
  • Anti-Arrhythmia Agents / therapeutic use
  • Defibrillators, Implantable*
  • Drug Therapy, Combination
  • Electric Countershock / adverse effects*
  • Electric Countershock / instrumentation
  • Equipment Failure
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Sex Factors
  • Sotalol / administration & dosage
  • Sotalol / therapeutic use
  • Treatment Outcome

Substances

  • Adrenergic beta-Antagonists
  • Anti-Arrhythmia Agents
  • Sotalol
  • Amiodarone